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LIVER DISEASE
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Background: Acute hepatic failure secondary to paracetamol poisoning is associated with high mortality. C-
jun (NH2) terminal kinase (JNK) is a member of the mitogen-activated protein kinase family and is a key
intracellular signalling molecule involved in controlling the fate of cells.
Aim: To examine the role of JNK in paracetamol-induced acute liver failure (ALF).
Methods: A previously developed mouse model of paracetamol poisoning was used to examine the role of
JNK in paracetamol-induced ALF.
Results: Paracetamol-induced hepatic JNK activation both in human and murine paracetamol hepatotoxicity
and in our murine model preceded the onset of hepatocyte death. JNK inhibition in vivo (using two JNK
inhibitors with different mechanisms of action) markedly reduced mortality in murine paracetamol
hepatotoxicity, with a significant reduction in hepatic necrosis and apoptosis. In addition, delayed
administration of the JNK inhibitor was more effective than N-acetylcysteine after paracetamol poisoning in
mice. JNK inhibition was not protective in acute carbon tetrachloride-mediated or anti-Fas antibody-mediated
hepatic injury, suggesting specificity for the role of JNK in paracetamol hepatotoxicity. Furthermore,
disruption of the JNK1 or JNK2 genes did not protect against paracetamol-induced hepatic damage.
Pharmacological JNK inhibition had no effect on paracetamol metabolism, but markedly inhibited hepatic
tumour necrosis foctor a (TNF a) production after paracetamol poisoning.
Conclusions: These data demonstrated a central role for JNK in the pathogenesis of paracetamol-induced
liver failure, thereby identifying JNK as an important therapeutic target in the treatment of paracetamol
hepatotoxicity.
P
aracetamol (acetaminophen) poisoning is the most com-
mon cause of acute liver failure (ALF) in the UK and US.1 2
Deaths from paracetamol-induced ALF still occur despite
the availability of an effective antidote (N-acetylcysteine (NAC)
or methionine) and changes in the sale and packaging of
paracetamol in the UK. The only effective treatment for severe
cases of paracetamol hepatotoxicity is orthotopic liver trans-
plantation. However, transplantation has disadvantages includ-
ing limited donors, the commitment of often young recipients
to lifelong immunosuppression and psychiatric or medical
contraindications in approximately 50% of patients.3 Effective
alternative treatments for paracetamol-induced ALF are
urgently required.
The metabolic activation of paracetamol to N-acetyl-p-
quinoneimine (NAPQI) and subsequent conjugation with
glutathione is well characterised.4 However, the pathways
linking paracetamol metabolism with hepatic necrosis remain
elusive. Recent investigations have expanded our understand-
ing of the complex interplay between the pathways of toxin
metabolism, intracellular signalling and the host inflammatory
response.5 6 Inflammatory cells play a permissive role in hepatic
necrosis induced by paracetamol and early-response cytokines
and chemokines modulate both the injury and repair pro-
cesses.7 8 The mitogen-activated protein kinases are a family of
serine/threonine kinases that are evolutionarily conserved
signal-transducing enzymes unique to eukaryotes.9 10 The c-
jun (NH2) terminal kinases (JNKs) are one subgroup of the
mitogen-activated protein kinases.11 12 The JNK signal trans-
duction pathway is stimulated by a diverse range of extra-
cellular and intracellular stimuli including reactive oxygen
species (ROS), ultraviolet radiation and pro-inflammatory
cytokines. JNK controls many basic mammalian physiological
processes and phosphorylates specific subunits (c-Jun, JunB,
JunD and activating transcription factor 2) of the activating
protein 1 (AP-1) transcription factor,13–15 activating genes that
regulate diverse cellular functions including proliferation,16
survival17 18 and death.19 20 Recent in vitro data21–24 and in vivo
studies25–27 suggest a role for JNK in mediating hepatic injury.
Using a previously developed mouse model of paracetamol
poisoning,8 28 we demonstrate a central role for JNK in the
pathogenesis of paracetamol-induced ALF, thereby identifying
JNK as a potential therapeutic target.
MATERIALS AND METHODS
Human biopsy specimens and animal models
Archival human liver samples were obtained from the
Department of Pathology, University of Edinburgh,
Edinburgh, UK. All animal procedures were undertaken using
C57/BL6 mice, with approved licence from the Animal Scientific
Procedures Division of the Home Office (London, UK) using
mice aged 8–10 weeks. Generation of JNK12/2 and JNK22/2
mice by gene-targeting technology (on a C57/BL6 background)
has been described previously.29 As control, age- and sex-
matched wild-type (WT) littermates were used. After an
overnight fast, mice were injected intraperitoneally (IP) with
350 mg/kg of paracetamol dissolved in sterile phosphate-
Abbreviations: ALF, acute liver failure; ALT, alanine aminotransferase;
AP-1, activating protein 1; CCl4, carbon tetrachloride; D-JNKI1, c-jun N-
terminal kinase peptide inhibitor 1, D-stereoisomer; IP, intraperitoneal;
JNK, c-jun (NH2) terminal kinase; NAC, N-acetylcysteine; NAPQI, N-
acetyl-p-quinoneimine; PBS, phosphate-buffered saline; ROS, reactive
oxygen species; TNFa, tumour necrosis factor a; TNFR1, TNF receptor 1;
WT, wild type
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buffered saline (PBS) and warmed to 42 C˚ as described
previously,28 with carbon tetrachloride (CCl4) at a ratio of 1:3
with olive oil at a dose of 1 ml/g body weight as described
previously30 or with anti-Fas antibody (0.5 mg/g body weight;
BD Pharmingen, UK). Two JNK inhibitors were used in this
study: SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one) purchased
from Calbiochem (San Diego, California, USA) and D-JNKI1 (c-
Jun N-terminal kinase peptide inhibitor 1, D-stereoisomer)
inhibitor purchased from Axxora (Nottingham, UK). The
vehicle control for SP600125 was 40% polyethylene glycol
(PEG; Sigma, UK) in PBS. The control for D-JNKI1 was D-TAT
control peptide (Axxora) in PBS. In experiments utilising
delayed JNK inhibition, pharmacological inhibitors or appro-
priate controls were administered IP 5 h after paracetamol
injection.
Analysis of liver injury
After IP injection, groups of mice were scored as follows by a
blinded observer for signs of systemic illness: clinically well (0
points), presence of piloerection (1 point), with additional
hunched posture (2 points) and lack of spontaneous movement
(3 points) 24 h after injection. Serum was stored at 280 C˚ until
use for determination of alanine aminotransferase (ALT) levels
by an automated enzyme assay (Olympus 20700 analyser
(Olympus UK Ltd, Southall, UK)). Two lobes from each liver
were fixed in 4% paraformalydehyde before routine histological
processing. Histological grading of hepatic necrosis was
performed by two blinded observers using H&E-stained
sections as follows: ,30% of the total area necrotic (1
point); 30–60% of the total area necrotic (2 points); .60%
of the total area necrotic (3 points). Ten random fields
were counted independently by two blinded observers to
determine the number of apoptotic cells. Whole-liver homo-
genates were prepared and the Cell Death Detection ELISA
(Roche, Welwyn Garden City, UK; quantitative detection of
histone-associated DNA fragments in mononucleosomes
and oligonucleosomes) was used as per the manufacturer’s
instructions.
Protein analysis
Paraffin-wax-embedded sections were deparaffinised and sub-
jected to microwave antigen retrieval in citrate buffer. The
primary antibodies were rabbit polyclonal anti-phospho-JNK
(Biosource, Nivelles, Belgium) and antiparacetamol–protein
adduct antibodies (HyCult Biotechnology, Uden, Netherlands).
Species-appropriate isotype control antibodies were also used
for each experiment. Western blot analysis was undertaken
by using the following primary antibodies: rabbit polyclonal
anti-phospho-JNK 1&2 [pTpY183/185] (Biosource), rabbit poly-
clonal anti-phospho-p38 antibody [pTpY180/182] (Biosource,
Belgium) and rabbit polyclonal anti-b-actin antibody
(Sigma, Gillingham, UK). JNK activity was measured as
described previously.31 Liver was homogenised in PBS with a
protease inhibitor cocktail (Roche), and levels of immunor-
eactive tumour necrosis factor a (TNFa) and interferon c
(IFNc) were measured in the supernatants by ELISA
according to manufacturer’s instructions (R&D systems,
Abingdon, UK).
Statistical analysis
Results are presented as means (SEM). Significance of the
differences between means was assessed using one-way
analysis of variance or two-tailed Student’s t test. Values of
p,0.05 were considered significant. Unless stated otherwise,
studies were performed on 3–6 independent occasions using 6–
8 mice per group.
RESULTS
Paracetamol induces hepatic JNK activation in human
and murine liver and precedes the onset of hepatocyte
death
To determine whether JNK activity is increased during
paracetamol-induced liver injury, we examined phospho-JNK
expression. In a normal human liver, constitutive JNK
phosphorylation occurs in areas surrounding the central veins
(fig 1A). Cytoplasmic and dense nuclear staining was observed
within hepatocytes. After paracetamol-induced ALF, there was
a marked increase in hepatocyte cytoplasmic and nuclear
phospho-JNK staining compared with the control normal liver
(fig 1B; n = 8 cases in each group). We also examined JNK
activation in a murine model of paracetamol-induced hepatic
injury. Phospho-JNK expression was negligible in the control
mouse liver (fig 1C). Similar to human cases, paracetamol-
injured mouse liver demonstrated marked upregulation of
phospho-JNK in the hepatocyte nuclei and cytoplasm in the
areas surrounding the central veins (fig 1D). The time course of
JNK activation after paracetamol-induced injury was exam-
ined: hepatic JNK activity drastically increased after paraceta-
mol administration, with peak activity 2 h after injection (fig 1E
and inset). JNK activity then returned towards baseline levels
by 24 h. Comparison with the time course of biochemical liver
injury (determined by serum ALT) showed peak ALT 5 h after
paracetamol injection (fig 1F).
Pharmacological inhibition of JNK activity in vivo
markedly reduces murine mortality and liver injury
To assess the pathogenic significance of the observed increase
in JNK activity, we used two pharmacological inhibitors of JNK
that differ in their mechanisms of action. SP600125 is a small-
molecule reversible ATP-competitive inhibitor,32 33 whereas D-
JNKI1 is a peptide inhibitor that inhibits the interaction of JNK
with its substrates.34 Immunohistochemistry for hepatic phos-
pho-JNK demonstrated potent inhibition of JNK phosphoryla-
tion by SP600125 2 h after paracetamol treatment compared
with control (fig 2A,B) and was confirmed by radioactive
kinase assay (fig 2C) and western blotting for phospho-JNK
(fig 2D). Importantly, pretreatment with SP600125 did not
inhibit phosphorylation of the other major stress-activated
protein kinase in the liver, p-38 (fig 2D). To determine the
potential clinical significance of JNK activation after para-
cetamol poisoning, the JNK inhibitors (or control) were
injected 1 h before paracetamol administration, and mortality
was assessed over 72 h. Inhibition of JNK activity with either
SP600125 or D-JNKI1 drastically reduced mortality compared
with the vehicle control (fig 2E). In addition, sickness scores
were assessed at 24 h, and the SP600125 and D-JNKI1 inhibitor
groups showed significantly lower sickness scores than the
vehicle control group (fig 2F).
To further evaluate the striking survival benefit of JNK
inhibition after paracetamol administration, liver injury was
assessed after JNK inhibition. SP600125 or D-JNKI1 dramati-
cally reduced histological liver injury and hepatic necrosis
scores compared with vehicle control (fig 3A,B). Furthermore,
hepatocyte necrosis, as assessed by serum ALT release, was also
reduced in the JNK inhibitor groups compared with vehicle
control (fig 3C). Hepatocyte apoptosis may occur during
paracetamol toxicity in the human and murine liver.35
Apoptotic cells were clearly visible in the control group 5 h
after paracetamol administration; however, apoptotic cells were
less abundant in the JNK inhibitor groups at this time point
(fig 3D). Counting of morphologically apoptotic cells confirmed
this finding, with a significant reduction in the number of
apoptotic hepatocytes in the inhibitor groups compared with
the control, 5 h after paracetamol administration (fig 3E).
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Further assessment of apoptosis by cell death ELISA using
whole-liver homogenates also demonstrated a significant
reduction in apoptosis in the JNK inhibitor groups 1, 2 and
5 h after paracetamol treatment compared with the control
(fig 3F, p,0.01).
Delayed administration of JNK inhibitor is more
effective than NAC in limiting liver injury
An important clinical problem in the management of para-
cetamol poisoning is the group of patients who present >15 h
after the overdose when the antidote, NAC, is much less
effective. We have previously used NAC in a mouse model of
paracetamol toxicity36 and demonstrated that beyond 5 h NAC
is no longer effective in preventing liver injury. Therefore, we
investigated whether delayed administration of the JNK
inhibitor is more effective than NAC when given after a
paracetamol overdose. Histological liver injury was less in
the NAC and SP600125 groups (fig 4A). Furthermore,
SP600125 was significantly more effective than NAC in
limiting liver injury after paracetamol poisoning when given
5 h after an overdose, as assessed by hepatic necrosis scoring
(fig 4B) and serum ALT release (fig 4C). However, JNK
inhibition was no longer effective 8 and 24 h after paracetamol
poisoning.
JNK inhibition is not protective in acute CCl4-mediated
or anti-Fas antibody-mediated hepatic injury
To determine whether JNK inhibition is protective in other
forms of acute liver injury, we examined JNK inhibition in
acute CCl4- and anti-Fas antibody-induced hepatic damage.
Similar to paracetamol, CCl4 is a hepatotoxin metabolised in
the liver by the cytochrome system, leading to the release of
toxic free radicals and oxidant-mediated hepatic injury. Also,
CCl4 injection increases JNK activity in the whole liver in vivo.
37
To assess the effect of JNK inhibition in CCl4-mediated liver
injury, mice received CCl4 (at a ratio of 1:3 with olive oil at a
dose of 1 ml/g body weight) 1 h after treatment with control,
SP600125 or D-JNKI1. Similar histological liver injury was
observed in all groups (fig 5A), and there was no significant
difference in hepatic necrosis scores (fig 5B) or biochemical
liver injury at 24 h (fig 5C). Further experiments were also
undertaken using CCl4 at a ratio of 1:3 with olive oil at a dose of
0.5 ml/g body weight, with no protection provided by JNK
inhibition.
Previous studies have suggested that the Fas death pathway
may play a role in the pathogenesis of paracetamol-induced
liver injury.38–40 Therefore, we specifically examined the role of
JNK inhibition in the anti-Fas antibody model of hepatic injury.
Administration of anti-Fas (Jo-2) antibody directly ligates and
Figure 1 Paracetamol induces hepatic c-jun
(NH2) terminal kinase (JNK) activation in
both human and murine paracetamol-
induced liver injury, and precedes the onset
of hepatocyte death. (A) Phospho-JNK (P-
JNK) expression in normal human liver and
(B) paracetamol-induced liver injury in
humans (n = 8 cases in each group). Scale
bar 400 mm. (C) P-JNK expression in mouse
liver 2 h after intraperitoneal (IP)
administration of control alone. (D) P-JNK
expression in mouse liver 2 h after treatment
with paracetamol (350 mg/kg IP). Scale bar
200 mm. (E) Time course of hepatic JNK
activation in mouse liver after paracetamol-
induced hepatic injury (350 mg/kg IP). Inset:
representative phosphorimage of hepatic
JNK (P-c-jun) activity in whole-liver
homogenates from paracetamol-treated
mice. (F) Time course of serum alanine
aminotransferase (ALT) release in mice after
paracetamol-induced liver injury (350 mg/
kg IP; *p,0.01).
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activates the CD95 death receptor pathway, resulting in massive
hepatocyte apoptosis within hours.41 42 Mice received anti-Fas
antibody 1 h after treatment with control, SP600125 or D-
JNKI1. Similar histological liver injury was observed in all
groups (fig 5D), and there was no significant difference in
hepatic necrosis scores (fig 5E) or biochemical liver injury at
6 h (fig 5F). Further experiments were also undertaken using
anti-Fas antibody at a dose of 0.25 mg/g body weight, with no
protection provided by JNK inhibition (data not shown).
Disruption of the JNK1 or JNK2 genes does not protect
against paracetamol-induced liver injury
The JNK protein kinases are encoded by three genes.11 The liver
expresses two of the three known JNK genes—JNK1 and JNK2.
To discuss in further detail the role of JNK1 and JNK2 in
paracetamol-induced hepatic failure, we studied JNK12/2 and
JNK22/2 mice (JNK1+2 double-null mice are embryonic lethal).
Liver histology showed no protection in the JNK12/2 and
JNK22/2 mice compared with WT mice (fig 6A), and no
significant difference in hepatic necrosis scores (fig 6B) or
biochemical liver injury between groups (fig 6C).
JNK inhibition does not affect synthesis of paracetamol–
protein adducts, but markedly inhibits TNFa production
in the liver after paracetamol-induced hepatic injury
Ingestion of paracetamol results in metabolism to NAPQI,
which is effectively detoxified by conjugation with glutathione.
However, in paracetamol poisoning, cytosolic and mitochon-
drial glutathione becomes depleted, allowing covalent binding
of NAPQI to hepatocellular proteins (paracetamol–protein
adducts).4 Although the exact mechanisms mediating para-
cetamol hepatotoxicity remain elusive, recent data have high-
lighted the important regulatory role of the immune system
and cytokine networks in determining outcomes after para-
cetamol-induced liver injury.8 28 36 39 43 Therefore, we examined
whether JNK inhibition interferes with the metabolism of
paracetamol by measuring paracetamol–protein adducts.44 No
paracetamol–protein adducts were seen in normal mouse liver
(fig 7A). However, the formation of paracetamol–protein
adducts (visible in hepatocytes around the central veins) was
similar in all groups 5 h after paracetamol administration
(vehicle control, SP600125 and D-JNKI1 groups; fig 7B–D).
We also explored in vivo which inflammatory cytokines may
be modulated by JNK inhibition in our model of paracetamol-
induced liver injury. Previous studies have implicated inter-
feron c (IFNc) in the pathogenesis of paracetamol-induced liver
injury.7 39 Hepatic IFNc levels were increased in all groups 2 h
after paracetamol administration compared with the control,
and remained increased throughout 24 h. No significant
difference in hepatic IFNc levels was observed between the
treatment groups at any of the time points studied (fig 7E).
TNFa is an inflammatory cytokine that may play a significant
pathogenic role in paracetamol hepatotoxicity,28 45 46 although
conflicting data have been reported. In vitro studies show that
TNFa induces JNK activation in hepatocytes.47 In addition to
the role of TNFa in apoptotic hepatocyte death, perhaps more
relevant to paracetamol-induced liver injury, the JNK/AP-1
signalling pathway can also mediate TNFa-induced necrotic
hepatocyte death.48 JNK activation can also induce TNFa
expression via AP-1.49 50 Therefore, we examined whether the
protective effect of JNK inhibition in paracetamol hepatotoxi-
city is mediated by modulation of TNFa expression. Hepatic
TNFa levels were significantly increased in the vehicle control
group 2 and 5 h after paracetamol administration compared
with baseline (0 h). However, there was significantly less
hepatic TNFa production in the JNK inhibitor groups 2 and 5 h
after paracetamol administration compared with the vehicle
control (fig 7F).
DISCUSSION
We have shown a central role for JNK in the pathogenesis of
paracetamol-induced ALF, thereby identifying JNK as a
potential therapeutic target in the treatment of paracetamol
hepatotoxicity. Our data indicated that: (1) paracetamol-
induced liver injury results in hepatic JNK activation in human
and murine tissue, which precedes the onset of hepatocyte
death; (2) pharmacological inhibition of JNK in vivo markedly
improved survival in a mouse model of paracetamol-induced
ALF and decreased both hepatic necrosis and apoptosis. The
protective effect of JNK inhibition was specific for paracetamol
hepatotoxicity as the inhibitors were not protective in acute
Figure 2 Pharmacological inhibition of c-jun (NH2) terminal kinase (JNK)
activity in vivo markedly reduces mortality in a mouse model of
paracetamol-induced acute liver failure. Mice were injected
intraperitoneally (IP) with vehicle control or SP600125 (30 mg/kg) 1 h
before IP injection with paracetamol solution (350 mg/kg). (A) Hepatic
phospho-JNK (P-JNK) expression in the vehicle control group 2 h after
paracetamol administration. (B) Hepatic P-JNK expression in the
SP600125 group 2 h after paracetamol administration. (C) Time course of
hepatic JNK activity in mice injected IP with vehicle control or SP600125
(30 mg/kg) 1 h before paracetamol administration (350 mg/kg). (D) Time
course of hepatic P-JNK and phospho-p38 in mice injected IP with vehicle
control or SP600125 (30 mg/kg) 1 h before paracetamol administration
(350 mg/kg). (E) Mortality at 72 h in mice injected IP with vehicle control,
SP600125 (30 mg/kg) or D-JNKI1 (c-Jun N-terminal kinase peptide
inhibitor 1, D-stereoisomer; 30 mg/mouse) 1 h before paracetamol
administration (450 mg/kg; n = 10 mice in each group). (F) Sickness scores
at 24 h in mice injected IP with vehicle control, SP600125 (30 mg/kg) or
D-JNKI1 (30 mg/mouse) 1 h before paracetamol administration (350 mg/
kg; n = 10 mice in each group). Each point represents an individual mouse.
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Figure 3 c-Jun (NH2) terminal kinase (JNK)
inhibition in vivo reduces hepatic necrosis
and apoptosis in paracetamol-induced acute
liver failure. Mice were injected
intraperitoneally (IP) with vehicle control,
SP600125 (30 mg/kg) or D-JNKI1 (c-jun N-
terminal kinase peptide inhibitor 1, D-
stereoisomer; 30 mg/mouse) 1 h before
paracetamol administration (350 mg/kg;
n = 6 mice in each group). (A) Liver histology
at 24 h after paracetamol. Scale bar
200 mm. (B) Hepatic necrosis scores at 24 h
after paracetamol administration
(*p,0.001). (C) Serum alanine
aminotransferase (ALT) release at 24 h after
paracetamol administration (**p,0.05). (D)
Liver histology at high magnification (6200)
5 h after paracetamol administration
demonstrating apoptotic cells (arrowed) in
the control vehicle-treated group. (E) Time
course of apoptotic cells/high power field
(HPF; ***p,0.01). (F) Time course of
apoptosis assessed by cell death ELISA
(quantitative detection of histone-associated
DNA fragments in mononucleosomes and
oligonucleosomes) from whole-liver
homogenates (***p,0.01).
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Figure 4 Delayed administration of c-jun
(NH2) terminal kinase (JNK) inhibitor is more
effective than N-acetylcysteine (NAC) in
limiting liver injury after paracetamol
poisoning in mice. Mice were treated with
paracetamol (350 mg/kg intraperitoneally)
and 5 h later administered control vehicle,
NAC or SP600125 (30 mg/kg; n = 6 mice in
each group). (A) Liver histology at 24 h after
paracetamol administration. Scale bar
200 mm. (B) Hepatic necrosis scores at 24 h
after paracetamol administration (*p,0.05).
(C) Serum alanine aminotransferase (ALT)
release 24 h after paracetamol
administration (*p,0.05).
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CCl4-mediated or anti-Fas antibody-mediated hepatic injury;
(3) delayed administration of JNK inhibitor is more effective
than NAC in limiting liver injury in mice; (4) disruption of
either the JNK1 or JNK2 genes was not protective; and (5)
inhibition of the JNK had no effect on paracetamol metabolism,
but inhibited hepatic TNFa production after paracetamol-
induced ALF.
Paracetamol poisoning is the most common cause of ALF in
the UK and USA, causing significant morbidity and mortality in
predominantly young people. Many patients present outside
the therapeutic window for the commonly used antidote, NAC.
Our data demonstrated that delayed administration of the JNK
inhibitor is more effective than NAC after paracetamol
poisoning in mice. Although NAC can be administered up to
15 h after a paracetamol overdose in clinical practice, we found
limited efficacy 5 h after paracetamol administration in the
mouse model. This is in keeping with our previously published
data,36 and relates to the truncated time course of liver injury in
mice compared with humans. Metabolic activation of para-
cetamol and the histological liver injury produced in mice is
similar to that observed in humans; however, the variability in
terms of the clinical context in which the paracetamol overdose
is taken and the genetic background of humans limits direct
extrapolations of our results to the treatment of patients.
Despite these limitations, our data indicate that further studies
of JNK activation in cases of paracetamol poisoning in humans
may lead to the development of new treatments and that
pharmacological inhibition of JNK may be of particular clinical
use in patients with delayed presentation after paracetamol
overdose.
Our data show prolonged hepatic activation of JNK after
paracetamol overdose in both the human and murine liver.
Interestingly, in the normal human liver phospho-JNK staining
was observed in hepatocytes surrounding the central veins, the
area in which paracetamol is preferentially activated by the
hepatic cytochrome P450 system. Hepatic JNK activation may
be a consequence of the oxidative stress produced during
paracetamol metabolism. ROS are widely recognised to induce
increased and/or prolonged JNK activation, possibly because of
inactivation of cellular phosphatases.25 Although ROS alone can
activate JNK, hepatic TNFa expression is increased in para-
cetamol-induced liver injury.51–53 TNFa is a potent inducer of
Figure 5 c-Jun (NH2) terminal kinase (JNK)
inhibition is not protective in acute carbon
tetrachloride (CCl4)- or anti-Fas antibody-
mediated hepatic injury. CCl4 model: mice
were administered CCl4 at a ratio of 1:3 with
olive oil at a dose of 1 ml/g body weight 1 h
after treatment with control, SP600125
(30 mg/kg) or D-JNKI1 (c-Jun N-terminal
kinase peptide inhibitor 1, D-stereoisomer;
30 mg/mouse; n = 6 mice in each group). (A)
Liver histology 24 h after CCl4
administration. Scale bar 200 mm. (B)
Hepatic necrosis scores 24 h after CCl4
administration (p = NS). (C) Serum alanine
aminotransferase (ALT) release 24 h after
CCl4-induced liver injury (p = NS). Fas
model: mice were administered anti-Fas
antibody (0.5 mg/g body weight) 1 hour
after treatment with control, SP600125
(30 mg/kg) or D-JNKI1 (30 mg/mouse; n = 6
mice in each group). (D) Liver histology 6 h
after anti-Fas antibody administration. Scale
bar 200 mm. (E) Hepatic necrosis scores 6 h
after anti-Fas antibody administration
(p = NS). (F) ALT release 6 h after anti-Fas
antibody-induced liver injury (p = NS).
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both JNK and ROS. Therefore, in the hepatic cytokine milieu
induced by paracetamol, a positive amplification loop may exist
whereby paracetamol-induced ROS leads to JNK activation and
TNFa expression via AP-1,49 50 resulting in further prolonged
massive JNK activation in the liver via TNF receptor signalling.
To investigate the potential pathogenic role of JNK activation
in the development of paracetamol-induced hepatic necrosis,
we used two different JNK inhibitors with different mechan-
isms of action (SP600125 and D-JNKI1). Both inhibitors have
been widely studied both in vivo and in vitro. Although the
specificity of pharmacological inhibitors can be questioned, we
found no reduction in the hepatic activation of another stress-
activated protein kinase, p38, after administration of the JNK
inhibitor and paracetamol. Furthermore, despite different
mechanisms of action, both JNK inhibitors conferred signifi-
cant survival benefit and profound protection against para-
cetamol-induced hepatic necrosis.
Several studies have shown the mechanistic importance of
the hepatic cytokine network in paracetamol-induced liver
injury. To investigate the mechanisms underlying the protective
effect of JNK inhibition in paracetamol hepatotoxicity, we
measured the hepatic expression of IFNc and TNFa. Both these
cytokines are induced in the liver after paracetamol poison-
ing.7 39 51–53 Furthermore, IFNc knockout mice are resistant to
paracetamol-induced liver injury.7 However, in our model, JNK
inhibition had no significant effect on hepatic IFNc. By
contrast, JNK inhibition significantly reduced hepatic TNFa
expression. We and others have shown increased TNFa
expression in the peripheral circulation and liver after
paracetamol poisoning.28 53 In the studies reporting a protective
effect of TNFa inhibition in paracetamol-induced liver injury,
the degree of protection was similar to that observed with JNK
inhibition in our study.45 51 52 However, the pathogenic role of
TNFa in paracetamol-induced hepatic necrosis remains con-
troversial. Studies using blocking antibodies and inhibitors of
TNFa have produced conflicting results, with both protection
and no effect being reported.51–53 Alternatively, some have
shown attenuated liver injury in mice lacking TNF receptor 1
(TNFR1) expression, while others, using a different strain of
mice, have shown increased liver injury in TNFR1 knockout
mice.45 54 Our data suggest that JNK inhibition may limit liver
injury via reduced TNFa expression, although in view of the
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Figure 6 Disruption of the JNK1 or JNK2
genes does not protect against paracetamol-
induced liver injury. Wild-type (WT),
JNK12/2 or JNK22/2 mice were
administered paracetamol (350 mg/kg
intraperitoneal), and livers and serum
harvested at 24 h (n = 6 mice in each group).
(A) Liver histology 24 h after paracetamol
administration. Scale bar 200 mm. (B)
Hepatic necrosis scores 24 h after
paracetamol administration (p = NS). (C)
Serum alanine aminotransferase (ALT)
release 24 h after paracetamol-induced liver
injury (p = NS).
Figure 7 c-Jun (NH2) terminal kinase (JNK)
inhibition does not affect the synthesis of
paracetamol–protein adducts, but markedly
inhibits the production of tumour necrosis
factor a (TNFa) in the liver after
paracetamol-induced hepatic injury. Mice
were injected intraperitoneally with control,
SP600125 (30 mg/kg) or D-JNKI1 (c-jun N-
terminal kinase peptide inhibitor 1, D-
stereoisomer; 30 mg/mouse) 1 h before
paracetamol administration (350 mg/kg;
n = 6 mice in each group). (A) Anti-
paracetamol–protein adduct staining in
normal, untreated mouse liver. Scale bar
200 mm. (B–D) Formation of anti-
paracetamol–protein adduct 5 h after
paracetamol administration. (E) Time course
of hepatic interferon c (IFNc) production
after paracetamol administration (p = NS).
(F) Time course of hepatic TNFa production
after paracetamol administration (*p,0.05).
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reduced initial liver injury with JNK inhibition it is difficult to
clarify a potential cause or an effect of the reduced TNFa
expression. In a recent study, Kaplowitz et al reported that JNK
inhibition limited paracetamol-induced liver injury, possibly by
interfering with translocation of members of the Bcl2 family
into the mitochondrial membrane.55 This study reported that
JNK inhibition protects TNFR1 knockout mice from paraceta-
mol-induced hepatic injury. However, TNFa expression levels
were not measured in this study. These data do not invalidate
our postulated mechanism as TNFa can also induce cell death
via TNFR2 signalling.56 57 Further studies are required to fully
understand the roles of TNFa-induced TNFR1 and TNFR2
signalling via JNK in paracetamol-induced liver failure.
The protective effect of JNK inhibition in paracetamol-
induced liver injury was not translated into protection in other
models of liver injury. JNK inhibition was not protective after
Fas ligation and CCl4 injection, which confirms previous
reports.23 55 Similar to paracetamol hepatotoxicity, TNFa has
been implicated in CCl4-mediated liver injury, but again
conflicting published data exist. Injection of soluble TNF
receptors limits CCl4 hepatotoxicity
58; however, pre-injection
of anti-TNF antibodies has no protective effect.59 Furthermore,
studies of TNF receptor 1, 2 or double-knockout or TNFa-
knockout mice have demonstrated either no effect or protection
after CCl4-mediated liver injury.
60–63 In contrast with our data
on JNK inhibition in the context of paracetamol hepatotoxicity,
we observed no reduction in hepatic TNFa expression after JNK
inhibition and CCl4 injection (data not shown).
JNK induces the expression of TNFa in several cell
types.49 50 64–66 Transfection of liver-specific macrophages
(Kupffer cells) with constitutively active adenovirus expressing
the upstream JNK-kinase, MKK-7, induces TNFa production,
and JNK inhibition reduces leptin-induced TNFa production in
the same cell type.65 In view of our data, it is noteworthy that a
functional redundancy of JNK genes in TNFa production from
macrophages has been reported.64 We speculate that pan-
inhibition of the JNK signalling pathway down regulates TNFa
expression by Kupffer cells and reduces paracetamol-induced
liver injury. However, this may be difficult to study in vivo as
Kupffer cell-depleted mice are protected from paracetamol-
induced hepatic necrosis.67 Therefore, future studies with
conditional cell-specific JNK knockouts in the liver may aid
further analysis in this regard.
The liver expresses two JNK genes—JNK1 and JNK2.
Although complete JNK inhibition by SP600125 and D-JNKI1
was protective, liver injury was similar in JNK12/2 and JNK22/2
mice compared with WT mice. Others have recently reported
partial limitation of paracetamol-induced liver injury in JNK22/2
mice or in mice treated with JNK2 antisense RNA, but this
protection was not as effective as pan-JNK inhibition with
either pharmacological inhibitors or JNK antisense RNA.55 The
context and cell-specific effects of JNK1 or JNK2 knockout on
cell death have been reported. Our data suggest redundancy
between the JNK1 and JNK2 signalling pathways in the
context of paracetamol-induced liver injury. We were unable
to directly address this further in our study as JNK12/222/2
(double null) mice are embryonic lethal, and therefore future
studies with conditional knockouts in the liver may aid further
analysis of the relative roles of these genes in paracetamol-
induced hepatic necrosis.
In summary, we found a massive increase in hepatic JNK
activity during paracetamol-induced hepatic failure in a murine
model. Inhibition of hepatic JNK with either a pharmacological
or peptide inhibitor significantly reduced liver injury and
mortality without affecting paracetamol bioactivation, and
confirms and expands recently published data.55 The hepato-
protective effect of JNK inhibition may be by a specific
reduction in hepatic TNFa expression. From a clinical stand-
point, we have shown that JNK inhibition is more efficacious in
reducing liver injury at later time points when the traditional
antidote NAC is no longer effective. These data demonstrate
that JNK plays a crucial role in hepatocyte death after
paracetamol poisoning, and suggest that JNK inhibition may
find clinical applications in patients who present late after
overdose or in whom timing of the overdose is unclear.
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